Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035
Shots:
- Alphamab to receive upfront- milestones and royalties on sales of KN035 (ASC22). Ascletis to get exclusive development and commercialization rights for Alphamab’s KN035 (ASC22) in Greater China
- Alphamab will be responsible to manufacture and commercialize ASC22 (KN035) in Greater China and Ascletis to receive economics (Ex-China) from Alphamab on its regulatory approval in China
- KN035 (ASC22) is an anti-PD-L1 mAb- targeted to treat chronic Hepatitis B and viral diseases across the US- China and Japan
Ref: PRNewswire | Image: Select Science
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
